Francisco J. Esteva/LinkedIn
Jun 15, 2025, 10:59
Francisco J. Esteva: Cautiously Optimistic About BioNTech’s $1.25 Billion Move Into Cancer Care
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared a post on LinkedIn:
“As an oncologist, I’m encouraged – but cautiously optimistic – about what this could mean for our patients.
BioNTech, best known for its COVID-19 mRNA vaccine, just announced a $1.25 billion acquisition of CureVac, another mRNA pioneer. But this time, their goal isn’t pandemic response. It’s cancer care.
This merger unites two leading mRNA platforms to accelerate the development of personalized immunotherapies – treatments that could teach the immune system to recognize and attack cancer cells based on each patient’s unique tumor profile.
What’s promising:
Potential for individualized cancer vaccines
Expanded access to early-phase clinical trials
Momentum in targeting hard-to-treat and recurrent cancers with less toxicity
What remains urgent:
Rigorous data on clinical outcomes
Equity in trial access and affordability
Continued transparency about timelines and patient impact
mRNA technology changed how we think about infectious disease. Now we may be witnessing a turning point in oncology – if the science can deliver, and if we keep patients at the center.
Let’s watch this space closely – and ensure that innovation stays aligned with care.
Follow for updates as this evolves.”
More posts featuring Francisco J. Esteva.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 10:39
Jun 15, 2025, 10:30
Jun 15, 2025, 09:18
Jun 15, 2025, 08:40